Berry v. Blue Cross of Washington and Alaska

815 F. Supp. 359, 1993 U.S. Dist. LEXIS 2235, 1993 WL 49885
CourtDistrict Court, W.D. Washington
DecidedFebruary 25, 1993
DocketC92-1940Z
StatusPublished
Cited by8 cases

This text of 815 F. Supp. 359 (Berry v. Blue Cross of Washington and Alaska) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Berry v. Blue Cross of Washington and Alaska, 815 F. Supp. 359, 1993 U.S. Dist. LEXIS 2235, 1993 WL 49885 (W.D. Wash. 1993).

Opinion

ORDER

ZILLY, District Judge.

This matter comes before the Court on plaintiffs’ motion for. summary judgment, docket no. 19, and defendant’s cross-motion for summary judgment, docket no. 25. The Court hereby finds that there are material issues of fact in dispute and DENIES both motions for summary judgment.

BACKGROUND

Plaintiff Diana Berry is a 43-year-old clinical psychologist. Her husband,- Miles McFall, is a clinical psychologist employed by the United States government at the Veterans’ Administration Hospital in Seattle. Ms. Berry, and Mr. McFall are enrolled under a health plan issued pursuant to the Federal Employees Health Benefits Act (FEHBA), 5 U.S.C. § 8901 et seq. The specific plan that *360 covers Ms. Berry is managed by the Blue Cross and Blue Shield Association (BCBSA), with Blue Cross of Washington and Alaska furnishing local administration.

Ms. Berry was diagnosed in July 1992 as suffering from epithelial ovarian cancer. A complete abdominal hysterectomy and standard dose chemotherapy failed to contain the growth of the tumors, and Ms. Berry’s doctors recommended that she undergo high dose chemotherapy with an autologous bone marrow transplant (HDCT-ABMT). This procedure involves extraction and storage of the patient’s own bone .marrow, preserving the healthy bone marrow for later reinfusion, treating the patient with high doses of chemotherapy, which may damage or destroy the patient’s remaining bone marrow, and reipjeeting the patient with her own healthy, preserved bone marrow after the HDCT has been completed. Declaration of Elizabeth J. Shpall, M.D., ¶ 14.

On November 20, 1992, plaintiffs’ counsel wrote to defendant BCBSA requesting preauthorization for Ms. Berry’s proposed HDCT-ABMT. Plaintiffs’ Opening Brief, Ex. 1, Declaration of John G. Bergmann, docket no. 19. Blue Cross responded by a letter dated December 2, 1992, in which it requested additional information concerning Ms. Berry’s condition and the proposed course of treatment. Ex. 2, Bergmann Decl. On December 11, 1992, plaintiffs’ counsel wrote to Blue Cross and enclosed the requested information. Ex. 3, Bergmann Decl. Plaintiffs’ counsel received a facsimile of a letter dated December 12, 1992, from BCBSA, in which defendant denied Ms. Berry’s request for HDCT-ABMT. Ex. 4, Bergmann Decl. The letter stated that the 1992 Federal Employee Service Benefit Plan excluded coverage for ABMT treatment for plaintiffs cancer. On December 19, 1992, BCBSA initiated a review of its denial of coverage with the United States Office of Personnel Management (OPM). OPM upheld the denial of coverage in a decision issued on December 23, 1992. OPM Record, Attachment 1, Defendant’s Opening Brief, Ex. 1.

Plaintiffs concede that the 1992 Service Benefit Plan excludes Ms. Berry’s condition from HDCT-ABMT treatment. 1 However, they argue that they never saw or received a copy of the 1992 Service Benefit Plan prior to November, 1992, when their counsel advised them to request a copy. Declaration of Miles McFall, ¶ 8. They assert that they had instead received and relied on a copy of a booklet entitled “Plain Talk,” produced and distributed by BCBSA, that summarizes and describes the benefits of their health plan. Plaintiffs allege that they have received “Plain Talk” booklets annually since 1985, when Mr. McFall first enrolled in the Blue Cross plan. Id.

Unlike the “Service Benefit Plan,” the “Plain Talk” booklet does not differentiate between different types of bone marrow transplants. According to the booklet, bone marrow transplants are a covered benefit. Page 20 of the booklet contains the following paragraph:

ORGAN TRANSPLANTS If you need one of the following human organ transplants ( ... bone marrow ...) Standard Option will help you pay for it. However, if you need a ... bone marrow ... transplant, you or your physician must obtain written prior approval from the local Blue Cross and Blue Shield Plan before the treatment has begun. Prior approval should be obtained from the local Plan located in the area in which you will receive treatment (addresses begin on page 60). There’s a $100,000 maximum for hospital and physician inpatient charges re *361 lated to surgical transplant procedures that require prior approval Please see page 16 of the Service Benefit Plan brochure for more details.

Ex. 6, Bergmann Decl. (emphasis in original). Plain Talk also contains the following section, at pages 48-49, under the heading “exclusions”:

We don’t cover services and supplies that are:

For or related to surgical transplant procedures, including artificial or human organs or tissues, except for heart, bone marrow, lung, liver, heart-lung, or pancreas transplant procedures, which require prior approval and human cornea and kidney transplants.

Ex. 7, Bergmann Decl. (emphasis in original).

Defendant does not argue that the language of Plain Talk excludes HDCT-ABMT treatment. Instead, BCBSA argues that the Service Benefit Plan, which excludes such coverage, is the only legally relevant statement of the benefits to which Ms. Berry is entitled.

Resolution of this matter turns on whether the Plain Talk booklet or the Service Benefit Plan controls Ms. Berry’s health plan coverage.

STANDARD OF REVIEW

Under FEHBA, the United States, through the United States Office of Personnel Management (OPM), enters into annual federal procurement contracts with various private health care carriers in order to offer health benefit plans with a variety of coverage levels and costs to federal employees. 5 U.S.C. § 8903. Under FEHBA, a carrier must pay a benefits claim if OPM finds that the contract entitles an individual to such payment. 5 U.S.C. § 8902(j). OPM has established by regulation an administrative review process for an individual who believes that a carrier has improperly denied a claim. 5 C.F.R. § 890.105 (1992). In this case, OPM considered an appeal of Ms. Berry’s case and affirmed the denial of benefits. This denial represents a final determination by an administrative agency.

Several courts have held that OPM interpretations of FEHBA plans are subject to review under the arbitrary and capricious standard. Carolyn Arrington v. Group Hospitalization and Medical Services, Inc., 806 F.Supp. 287 (D.D.C.1992); Dixie L. Roseberry v. Blue Cross and Blue Shield of Nebraska, N o. 8:CV 92-371 (D.Neb. Dec. 18, 1992). OPM, as the agency charged with ensuring health care coverage for federal employees, has the duty and expertise to interpret the language of its contracts. The opinions of OPM regarding interpretation of its contracts with carriers are entitled to deference.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Toohey v. WYNDHAM WORLDWIDE CORP. HEALTH & WELFARE
727 F. Supp. 2d 978 (D. Oregon, 2010)
Toohey v. Wyndham Worldwide Corp. Health & Welfare Plan
727 F. Supp. 2d 978 (D. Oregon, 2010)
Goldinger v. Datex-Ohmeda Cash Balance Plan
701 F. Supp. 2d 1205 (W.D. Washington, 2010)
In Re LymeCare, Inc.
301 B.R. 662 (D. New Jersey, 2003)
Lancaster v. United States Shoe Corp.
934 F. Supp. 1137 (N.D. California, 1996)
Adams v. JC Penney Co., Inc.
865 F. Supp. 1454 (D. Oregon, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
815 F. Supp. 359, 1993 U.S. Dist. LEXIS 2235, 1993 WL 49885, Counsel Stack Legal Research, https://law.counselstack.com/opinion/berry-v-blue-cross-of-washington-and-alaska-wawd-1993.